WALTHAM, Mass., Feb. 21, 2017-- TESARO, Inc., an oncology-focused biopharmaceutical company, today announced its participation in two upcoming investor conferences. The Raymond James 38 th Annual Institutional ...
- Investor's Business Daily•5 days ago
Pfizer and Tesaro could follow AstraZeneca which, early Friday, unveiled strong results from a trial of Lynparza in breast cancer.
- TheStreet.com•5 days ago
AstraZeneca shares, meanwhile, were less-than-moved by the news.
TSRO : Summary for TESARO, Inc. - Yahoo Finance
Tesaro, Inc. (TSRO)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
|Bid||186.89 x 100|
|Day's Range||188.26 - 192.78|
|52 Week Range||35.50 - 192.94|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||-25.93|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|